

ICU (median age 1.2 years; $p < 0.001$, Mann-Whitney U test). An exploratory logistic regression analysis on ICU admittance, adjusted for age, confirmed a strong association between RSV genotype ON1 and ICU admittance (adjusted odds ratio 8.4; 95% CI 1.5%–46.6%; $p = 0.015$). However, this significant difference should be interpreted with caution for 2 reasons: 1) samples from patients in wards other than an ICU originated mainly in the Würzburg area, whereas samples from patients in ICUs were received from pediatric hospitals in various regions of Bavaria; 2) clinical information on patients not in ICUs was not available for assessment of whether the difference persisted when taking into account other risk factors for severe RSV disease.

In summary, the novel RSV A genotype ON1 containing a 72-nt duplication in the G gene was not found during 2010–11, but it constituted already 10.1% of all RSV A strains in a patient cohort from Bavaria, Germany, in the next season, 2011–12. In the context of the primary report of ON1 in Ontario, Canada (3), and the GenBank entry from Japan, our data suggest worldwide emergence of ON1. The almost complete worldwide replacement of circulating RSV B genotypes with the BA strain containing a comparable 60-nt duplication, which began in 1999, suggests that these duplications provide a selective advantage (2). Thus, molecular analysis of circulating RSV strains should be continued to determine whether ON1 has the potential to replace other RSV A strains in the years to come as did RSV B genotype BA during the past decade.

Acknowledgments

We thank the team of the viral diagnostic laboratory for skillful and dedicated assistance, and we thank the hospital physicians from the Bavarian PICU Study Group on Influenza and Other Viral ARI for providing data on pediatric ICU patients.

The study was supported by the Robert Koch Institute from funds of the Federal Ministry of Health (FKZ 1369-393). Data from the pediatric ICU were collected in the frame of a study financially supported by GlaxoSmithKline Vaccines, Wavre, Belgium.

**Christiane Prifert,
Andrea Streng,
Christine D. Krempl,
Johannes Liese, and
Benedikt Weissbrich**

Author affiliation: University of Würzburg, Würzburg, Germany

DOI: <http://dx.doi.org/10.3201/eid1906.121582>

References

1. Trento A, Galiano M, Videla C, Carballal G, Garcia-Barreno B, Melero JA, et al. Major changes in the G protein of human respiratory syncytial virus isolates introduced by a duplication of 60 nucleotides. *J Gen Virol.* 2003;84:3115–20. <http://dx.doi.org/10.1099/vir.0.19357-0>
2. Trento A, Casas I, Calderon A, Garcia-Garcia ML, Calvo C, Perez-Brena P, et al. Ten years of global evolution of the human respiratory syncytial virus BA genotype with a 60-nucleotide duplication in the G protein gene. *J Virol.* 2010;84:7500–12. <http://dx.doi.org/10.1128/JVI.00345-10>
3. Eshaghi A, Duvvuri VR, Lai R, Nadarajah JT, Li A, Patel SN, et al. Genetic variability of human respiratory syncytial virus A strains circulating in Ontario: a novel genotype with a 72 nucleotide G gene duplication. *PLoS ONE.* 2012;7:e32807. <http://dx.doi.org/10.1371/journal.pone.0032807>
4. Peret TC, Hall CB, Schnabel KC, Golub JA, Anderson LJ. Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. *J Gen Virol.* 1998; 79:2221–9.
5. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: Molecular Evolutionary Genetics Analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. *Mol Biol Evol.* 2011;28:2731–9. <http://dx.doi.org/10.1093/molbev/msr121>

Address for correspondence: Benedikt Weissbrich, Institute of Virology and Immunobiology, University of Würzburg, Versbacher Str. 7, 97078 Würzburg, Germany; email: weissbrich@vim.uni-wuerzburg.de

Travel-related *Neisseria meningitidis* Serogroup W135 Infection, France

To the Editor: A multinational outbreak of infection with *Neisseria meningitidis* serogroup W135 belonging to the sequence type (ST) 11 clonal complex started in the year 2000 among pilgrims to Mecca, Saudi Arabia, and their contacts and continued in 2001 in countries of sub-Saharan Africa (primarily Burkina Faso) (1). Thereafter, infection caused by these isolates decreased (2), but quadrivalent meningococcal vaccine (against serogroups A, C, Y, and W135) was recommended for pilgrims and travelers to countries in the meningitis belt of Africa, which spans sub-Saharan Africa from Ethiopia to Senegal. After 2001, infections caused by serogroup A predominated in the meningitis belt, but isolates of serogroup X also emerged (3); isolates of serogroup W135/ST11 increased again in Niger in 2010 (4).

During January 1–March 11, 2012, >4,000 suspected cases of meningococcal disease caused mainly by serogroup W135 were reported in countries of the African meningitis belt, including Benin, Burkina Faso, Mali, and Côte d'Ivoire (5). We present extensive bacteriologic and molecular characterization of *N. meningitidis* W135 isolates from 6 patients with meningococcal disease reported in France since January 2012; we also present typing data from 8 cases of meningitis in Côte d'Ivoire. None of the patients had received meningococcal vaccine.

The cases in France were neither epidemiologically nor geographically linked; 4 were in residents of the Paris region. All cases were linked to recent travel to sub-Saharan Africa by the patient or patient contacts; 4 patients reported recent travel to Benin, Senegal,

Table. Characteristics of serogroup W135 *Neisseria meningitidis* isolates from patients in France and Côte d'Ivoire, 2012*

Patient no.	Location†	Date of illness onset	Travel history	Date of return from travel	Patient age/sex	Test site	<i>N. meningitidis</i> isolate test results						
							Sero	ST	CC	PorA VR1	PorA VR2	FetA	penA
1	France/ Paris region	Jan 14	Benin	2011 Dec 28	1 y/M	CSF	2a	11	11	5	2	F1-1	1
2	France/ Loire	Feb 15	Senegal	Feb 12	62 y/F	Blood	2a	11	11	5	2	F1-1	1
3	France/ Rhône-Alpes	Feb 19	Senegal	Feb 19	53 y/F	Blood	2a	11	11	5	2	F1-1	1
4	France/ Paris region	Feb 27	Mali	Feb 23	4 y/M	AF	2a	11	11	5	2	F1-1	1
5	France/ Paris region	Mar 3	Mali (family)	UNK	5 y/F	CSF	2a	11	11	5	2	F1-1	1
6	France/ Paris region	Mar 6	Senegal (father)	Feb 26	4 mo/F	CSF	2a	11	11	5	2	F1-1	1
7	Côte d'Ivoire/ Kouto	Feb 3	UNK	NA	12 y/M	CSF	2a	11	11	5	2	F1-1	1
8	Côte d'Ivoire/ Korhogo	Feb 3	UNK	NA	18 y/M	CSF	2a	11	11	5	2	F1-1	1
9	Côte d'Ivoire/ Kouto	Feb 23	UNK	NA	7 y/F	CSF	2a	11	11	5	2	F1-1	1
10	Côte d'Ivoire/ Kouto	Feb 24	UNK	NA	65 y/F	CSF	2a	11	11	5	2	F1-1	1
11	Côte d'Ivoire/ Kouto	Feb 24	UNK	NA	1 y/F	CSF	2a	11	11	5	2	F1-1	1
12	Côte d'Ivoire/ Tengrela	Feb 24	UNK	NA	19 y/F	CSF	2a	11	11	5	2	F1-1	1
13	Côte d'Ivoire/ Tengrela	Feb 24	UNK	NA	3 y/M	CSF	2a	11	11	5	2	F1-1	1
14	Côte d'Ivoire/ Tengrela	Feb 24	UNK	NA	5 y/M	CSF	2a	11	11	5	2	F1-1	1

*All patients had meningitis except patients 2 and 3, who had bronchopneumonia and septicemia, and patient 4, who had arthritis. Sero, serotype; ST, sequence type; CC, clonal complex; VR, variable region; UNK, unknown; CSF, cerebrospinal fluid; AF, articular fluid; NA, not applicable.

†Country/region where case was reported.

gal, or Mali (Table). The 2 other cases were in a 4-month-old infant whose father had returned from Senegal 2 weeks before the onset of the disease and in a 5-year-old child who had several family members who visited Mali regularly, although no recent travel was documented. The delay between the return to France and the onset of the disease was <5 days except for 1 patient (17 days).

N. meningitidis isolates were recovered from blood, cerebrospinal fluid, or articular fluid from all 6 patients in France (Table). Two patients had septicemia after bronchopneumonia, but no respiratory samples were available. One patient had arthritis that

was also described in his sister, but no samples were available from the sister. Extrameningeal forms of illness caused by W135/ST11 isolates have been described (6). For the patients in Côte d'Ivoire, bacteria were isolated from cerebrospinal fluid during weeks 5–8 in 2012; the patients lived in 3 districts of the country (Kouto, Korhogo, and Tengrela). Mean age was 20.9 years (range 0.33–62) for the patients in France and 16.25 years (range 1–65) for those in Côte d'Ivoire.

Molecular typing was performed by multilocus sequence typing (MLST) using the PubMLST database (<http://pubmlst.org/neisseria>); typing included the 7 usual genes of

MLST, PorA variable regions 1 and 2, and *penA* and *fetA* genes. Results were obtained by using cultured bacteria for all but 1 case in France. All isolates from France and Côte d'Ivoire shared the same tested markers. Eight other cases of infection with serogroup W135 were found in France during the same period, but the patients had no travel history, and all isolates showed different markers (M.-K. Taha, unpub. data).

Serogroup W135 strains are widely distributed worldwide; the emergence of these strains during the 2000s corresponded to a clonal expansion of 1 clone within the ST11 complex (7). The subsequent decline of W135/ST11

strains was associated with increased isolate diversification (8), which suggests a selective restriction of the dominant circulating strain (2). In France, the W135/ST11 strain was rare after 2005; no cases were culture confirmed in 2010, and the 2 cases that were confirmed in 2011 showed the FetA2-19 marker. However, isolates from Africa during 2000–2011 frequently showed the FetA1 marker; in sub-Saharan Africa, the decline of W135/ST11 isolates was also associated with isolates showing diversified FetA markers (M.-K. Taha, unpub. data). The reemergence in 2012 of W135/ST11 strains that had the FetA1-1 marker suggests an antigenic shift that may have involved membrane proteins other than FetA or other surface structures, such as the lipooligosaccharide. Such antigenic shifts were associated with increased incidence of serogroup C and serogroup Y meningococcal disease in the United States (9). Antigenic shift could be a marker of changes in virulence and transmission of meningococcal isolates. Extensive molecular typing of meningococcal isolates is more likely to detect antigenic shifts and escape variants that may undergo clonal expansion and therefore should be employed in outbreak investigations. Enhanced surveillance was setup in France to identify imported W135 cases.

Our findings indicate that travelers to the meningitis belt of sub-Saharan Africa may be at risk for infection with *N. meningitidis* of serogroup W135. A vaccination campaign using the meningococcal A conjugate vaccine is ongoing in this region (10), but a conjugate bivalent vaccine that includes W135 should also be considered. Vaccination of travelers to this region with quadrivalent meningococcal vaccine should be recommended.

Information regarding the patients and their contacts were provided by the clinicians, the French Institute for Public Health Surveillance (www.invs.sante.fr), and the Regional Health Agencies of Pays-de-

Loire, Rhône-Alpes and Ile-de-France. In Côte d'Ivoire, the work was supported by the Agence Médecine Préventive and the mobile laboratory; patient information was provided by clinicians at health districts and the National Institute of Public Health.

**Muhamed-Kheir Taha,
Adèle Kacou-N'Douba,
Eva Hong,
Ala Eddine Deghmane,
Dario Giorgini,
Sophia Lurette Okpo,
Tatiana Kangah,
and Mireille Dosso**

Author affiliations: Institut Pasteur, Paris, France (M.-K. Taha, E. Hong, A.E. Deghmane, D. Giorgini); and Institut Pasteur, Abidjan, Côte d'Ivoire (A. Kacou-N'Douba, S.L. Okpo, T. Kangah, M. Dosso)

DOI: <http://dx.doi.org/10.3201/eid1906.120515>

References

- Parent du Châtelet I, Traore Y, Gessner BD, Antignac A, Naccro B, Njanpop-Lafourcade BM, et al. Bacterial meningitis in Burkina Faso: surveillance using field-based polymerase chain reaction testing. *Clin Infect Dis*. 2005;40:17–25. <http://dx.doi.org/10.1086/426436>
- Traoré Y, Njanpop-Lafourcade BM, Adjogble KL, Lourd M, Yaro S, Nacro B, et al. The rise and fall of epidemic *Neisseria meningitidis* serogroup W135 meningitis in Burkina Faso, 2002–2005. *Clin Infect Dis*. 2006;43:817–22. <http://dx.doi.org/10.1086/507339>
- Meningitis in Chad, Niger and Nigeria: 2009 epidemic season. *Wkly Epidemiol Rec*. 2010;85:47–63.
- Collard JM, Maman Z, Yacouba H, Djibo S, Nicolas P, Jusot JF, et al. Increase in *Neisseria meningitidis* serogroup W135, Niger, 2010. *Emerg Infect Dis*. 2010;16:1496–8. <http://dx.doi.org/10.3201/eid1609.100510>
- World Health Organization. Meningococcal disease: situation in the African meningitis belt. 2012 Mar 23 [cited 2013 Mar 18]. http://www.who.int/csr/don/2012_03_23/en/index.html
- Vienne P, Ducos-Galand M, Guiyoule A, Pires R, Giorgini D, Taha MK, et al. The role of particular strains of *Neisseria meningitidis* in meningococcal arthritis, pericarditis, and pneumonia. *Clin Infect Dis*. 2003;37:1639–42. <http://dx.doi.org/10.1086/379719>
- Mayer LW, Reeves MW, Al-Hamdan N, Sacchi CT, Taha MK, Ajello GW, et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electrophoretic type-37 complex. *J Infect Dis*. 2002;185:1596–605. <http://dx.doi.org/10.1086/340414>
- Taha MK, Giorgini D, Ducos-Galand M, Alonso JM. Continuing diversification of *Neisseria meningitidis* W135 as a primary cause of meningococcal disease after emergence of the serogroup in 2000. *J Clin Microbiol*. 2004;42:4158–63. <http://dx.doi.org/10.1128/JCM.42.9.4158-4163.2004>
- Harrison LH, Jolley KA, Shutt KA, Marsh JW, O'Leary M, Sanza LT, et al.; Maryland Emerging Infections Program. Antigenic shift and increased incidence of meningococcal disease. *J Infect Dis*. 2006;193:1266–74. <http://dx.doi.org/10.1086/501371>
- Marc LaForce F, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to Group A *Neisseria meningitidis* in the African meningitis belt: a persistent problem with an imminent solution. *Vaccine*. 2009;27(Suppl 2):B13–9. <http://dx.doi.org/10.1016/j.vaccine.2009.04.062>

Address for correspondence: Muhamed-Kheir Taha, Invasive Bacterial Infections Unit, Institut Pasteur, 28 rue de Dr Roux, 75015 Paris, France; email: mktaha@pasteur.fr

***Clostridium difficile* Infection Associated with Pig Farms**

To the Editor: *Clostridium difficile* of PCR ribotype 078 causes enteric disease in humans and pigs (1,2); a recent pan-European study revealed that this type was the third most frequently found type of *C. difficile* (1). The finding of identical *C. difficile* PCR ribotype 078 isolates in piglets with diarrhea and in humans with *C. difficile* infection (CDI) led to the suggestion that interspecies transmission might occur (3,4). Because *C. difficile* can be detected in the immediate environment of pig farms, we investigated intestinal colonization with *C. difficile* in pigs and in pig farmers, their relatives, and their employees in the Netherlands.